Cargando…
Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomark...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916752/ https://www.ncbi.nlm.nih.gov/pubmed/36768921 http://dx.doi.org/10.3390/ijms24032603 |
_version_ | 1784886202117128192 |
---|---|
author | Nemutlu, Emirhan Ozaltin, Fatih Yabanoglu-Ciftci, Samiye Gulhan, Bora Eylem, Cemil Can Baysal, İpek Gök-Topak, Elif Damla Ulubayram, Kezban Sezerman, Osman Ugur Ucar, Gulberk Kır, Sedef Topaloglu, Rezan |
author_facet | Nemutlu, Emirhan Ozaltin, Fatih Yabanoglu-Ciftci, Samiye Gulhan, Bora Eylem, Cemil Can Baysal, İpek Gök-Topak, Elif Damla Ulubayram, Kezban Sezerman, Osman Ugur Ucar, Gulberk Kır, Sedef Topaloglu, Rezan |
author_sort | Nemutlu, Emirhan |
collection | PubMed |
description | Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomarkers for the diagnosis and follow-up of cystinosis based on multiomics studies. The study included three groups: newly-diagnosed cystinosis patients (patient group, n = 14); cystinosis patients under treatment (treatment group, n = 19); and healthy controls (control group, n = 30). Plasma metabolomics analysis identified 10 metabolites as candidate biomarkers that differed between the patient and control groups [L-serine, taurine, lyxose, 4-trimethylammoniobutanoic acid, orotic acid, glutathione, PE(O-18:1(9Z)/0:0), 2-hydroxyphenyl acetic acid, acetyl-N-formil-5-metoxikinuramine, 3-indoxyl sulphate]. As compared to the healthy control group, in the treatment group, hypotaurine, phosphatidylethanolamine, N-acetyl-d-mannosamine, 3-indolacetic acid, p-cresol, phenylethylamine, 5-aminovaleric acid, glycine, creatinine, and saccharic acid levels were significantly higher, and the metabolites quinic acid, capric acid, lenticin, xanthotoxin, glucose-6-phosphate, taurine, uric acid, glyceric acid, alpha-D-glucosamine phosphate, and serine levels were significantly lower. Urinary metabolomic analysis clearly differentiated the patient group from the control group by means of higher allo-inositol, talose, glucose, 2-hydroxybutiric acid, cystine, pyruvic acid, valine, and phenylalanine levels, and lower metabolite (N-acetyl-L-glutamic acid, 3-aminopropionitrile, ribitol, hydroquinone, glucuronic acid, 3-phosphoglycerate, xanthine, creatinine, and 5-aminovaleric acid) levels in the patient group. Urine metabolites were also found to be significantly different in the treatment group than in the control group. Thus, this study identified candidate biomarkers that could be used for the diagnosis and follow-up of cystinosis. |
format | Online Article Text |
id | pubmed-9916752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99167522023-02-11 Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis Nemutlu, Emirhan Ozaltin, Fatih Yabanoglu-Ciftci, Samiye Gulhan, Bora Eylem, Cemil Can Baysal, İpek Gök-Topak, Elif Damla Ulubayram, Kezban Sezerman, Osman Ugur Ucar, Gulberk Kır, Sedef Topaloglu, Rezan Int J Mol Sci Article Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomarkers for the diagnosis and follow-up of cystinosis based on multiomics studies. The study included three groups: newly-diagnosed cystinosis patients (patient group, n = 14); cystinosis patients under treatment (treatment group, n = 19); and healthy controls (control group, n = 30). Plasma metabolomics analysis identified 10 metabolites as candidate biomarkers that differed between the patient and control groups [L-serine, taurine, lyxose, 4-trimethylammoniobutanoic acid, orotic acid, glutathione, PE(O-18:1(9Z)/0:0), 2-hydroxyphenyl acetic acid, acetyl-N-formil-5-metoxikinuramine, 3-indoxyl sulphate]. As compared to the healthy control group, in the treatment group, hypotaurine, phosphatidylethanolamine, N-acetyl-d-mannosamine, 3-indolacetic acid, p-cresol, phenylethylamine, 5-aminovaleric acid, glycine, creatinine, and saccharic acid levels were significantly higher, and the metabolites quinic acid, capric acid, lenticin, xanthotoxin, glucose-6-phosphate, taurine, uric acid, glyceric acid, alpha-D-glucosamine phosphate, and serine levels were significantly lower. Urinary metabolomic analysis clearly differentiated the patient group from the control group by means of higher allo-inositol, talose, glucose, 2-hydroxybutiric acid, cystine, pyruvic acid, valine, and phenylalanine levels, and lower metabolite (N-acetyl-L-glutamic acid, 3-aminopropionitrile, ribitol, hydroquinone, glucuronic acid, 3-phosphoglycerate, xanthine, creatinine, and 5-aminovaleric acid) levels in the patient group. Urine metabolites were also found to be significantly different in the treatment group than in the control group. Thus, this study identified candidate biomarkers that could be used for the diagnosis and follow-up of cystinosis. MDPI 2023-01-30 /pmc/articles/PMC9916752/ /pubmed/36768921 http://dx.doi.org/10.3390/ijms24032603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nemutlu, Emirhan Ozaltin, Fatih Yabanoglu-Ciftci, Samiye Gulhan, Bora Eylem, Cemil Can Baysal, İpek Gök-Topak, Elif Damla Ulubayram, Kezban Sezerman, Osman Ugur Ucar, Gulberk Kır, Sedef Topaloglu, Rezan Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title | Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title_full | Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title_fullStr | Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title_full_unstemmed | Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title_short | Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis |
title_sort | metabolomic analyses to identify candidate biomarkers of cystinosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916752/ https://www.ncbi.nlm.nih.gov/pubmed/36768921 http://dx.doi.org/10.3390/ijms24032603 |
work_keys_str_mv | AT nemutluemirhan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT ozaltinfatih metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT yabanogluciftcisamiye metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT gulhanbora metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT eylemcemilcan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT baysalipek metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT goktopakelifdamla metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT ulubayramkezban metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT sezermanosmanugur metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT ucargulberk metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT kırsedef metabolomicanalysestoidentifycandidatebiomarkersofcystinosis AT topaloglurezan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis |